Consumer Marketing briefs

Share this article:
Boehringer Ingelheim sponsored development of an unbranded site,, aimed at “helping women learn more about healthy female sexuality.” The site, from the National Women's Health Resource Center and the Association of Reproductive Health Professionals, offers tips on talking to doctors. Boehringer is developing flibanserin for female sexual dysfunction.

SCA Personal Care North America partnered with Men's Health Network and prostate cancer education and support organization Us TOO International for an awareness campaign on urinary incontinence in men. The campaign features, a “virtual locker room” aimed at educating men. SCA Personal Care markets Tena brand bladder control products and services.

Novo Nordisk is sponsoring a branded Twitter feed written by racecar driver Charlie Kimball, who uses Novo's Levemir for type 1 diabetes, Advertising Age reported. Kimball had, at press time, 336 followers, which sports NovoLog and Levemir branding and fair balance info, but isn't following other users so as to avoid unsolicited responses—and the adverse event reporting requirements that they might trigger.  

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?